Based on the Aytu BioScience Inc stock forecast from 0 analysts, the average analyst target price for Aytu BioScience Inc is not available over the next 12 months. Aytu BioScience Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aytu BioScience Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Aytu BioScience Inc’s stock price was USD 2.13. Aytu BioScience Inc’s stock price has changed by -6.70% over the past week, -10.33% over the past month and +5,807,246.94% over the last year.
No recent analyst target price found for Aytu BioScience Inc
No recent average analyst rating found for Aytu BioScience Inc
Company Overview Aytu BioScience Inc
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado. Address: Denver Corporate Center III, Denver, CO, United States, 80237 Read Less
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT fo...Read More
Frequently Asked Questions About Aytu BioScience Inc (AYTU) Stock
Stock Target Advisor's fundamental analysis for Aytu BioScience Inc's stock is Bearish.
Unfortunately we do not have enough data on AYTU's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on AYTU's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on AYTU's stock to indicate if its overvalued.
The last closing price of AYTU's stock was USD 2.13.
The most recent market capitalization for AYTU is USD 0.01B.
Unfortunately we do not have enough analyst data on AYTU's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Aytu BioScience Inc's stock.
As per our most recent records Aytu BioScience Inc has 102 Employees.
Aytu BioScience Inc's registered address is Denver Corporate Center III, Denver, CO, United States, 80237.
You can get more information about it from Aytu BioScience Inc's website at https://aytubio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Aytu BioScience Inc (AYTU) Stock
Stock Target Advisor's fundamental analysis for Aytu BioScience Inc's stock is Bearish.
Unfortunately we do not have enough data on AYTU's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on AYTU's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on AYTU's stock to indicate if its overvalued.
The last closing price of AYTU's stock was USD 2.13.
The most recent market capitalization for AYTU is USD 0.01B.
Unfortunately we do not have enough analyst data on AYTU's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Aytu BioScience Inc's stock.
As per our most recent records Aytu BioScience Inc has 102 Employees.
Aytu BioScience Inc's registered address is Denver Corporate Center III, Denver, CO, United States, 80237.
You can get more information about it from Aytu BioScience Inc's website at https://aytubio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AYTU !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
